Heart Transplantation Outcomes for Fontan Patients When Using Contemporary Strategies: Heart-Liver Transplantation and Ventricular Assist Device Therapy.

Spencer J Hogue, Jason W Greenberg, Amir Mehdizadeh-Shrifi, Chet R Villa, Clifford Chin, Angela Lorts, Alexander R Opotowsky, David G Lehenbauer, David L S Morales
{"title":"Heart Transplantation Outcomes for Fontan Patients When Using Contemporary Strategies: Heart-Liver Transplantation and Ventricular Assist Device Therapy.","authors":"Spencer J Hogue, Jason W Greenberg, Amir Mehdizadeh-Shrifi, Chet R Villa, Clifford Chin, Angela Lorts, Alexander R Opotowsky, David G Lehenbauer, David L S Morales","doi":"10.1177/21501351241305127","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>With an increasing number of Fontan patients surviving into adulthood, the burden of end-stage heart failure is increasing. Prior studies have reported suboptimal heart transplantation (HTx) outcomes. Therefore, the authors describe their institutional experience of HTx in patients with Fontan circulation failure, including <i>en-bloc</i> heart-liver transplantation (HLTx) and pretransplant systemic ventricular assist device (SVAD) therapies.</p><p><strong>Methods: </strong>All consecutive Fontan-palliated patients undergoing HTx or HLTx between 2013 and 2022 at the authors' institution were included. Pretransplant characteristics and posttransplant outcomes were recorded.</p><p><strong>Results: </strong>Twenty-six transplant recipients, including 5 (19%) HLTx recipients, were identified. The majority (n = 16, 62%) of patients had a cardiac diagnosis of hypoplastic left heart syndrome. Seven (26%) patients were bridged to transplant on an SVAD; the median duration of support was 104 [IQR 39-543] days. Transplantation occurred at a median of 10.6 [IQR 6.8-15.6] years post-Fontan. Fourteen (54%) patients had ≥1 in-hospital complication and 4 (15%) patients required an in-hospital reoperation. Postdischarge reinterventions included tricuspid valve repair (n = 1, 4%) and retransplantation (n = 1, 4%). Two (8%) in-hospital mortalities [22 days (post-HLTx), 2.9 months (post-HTx] and 4 (15%) postdischarge mortalities [5.4 months, 3.1 years, 5.7 years, 7.1 years (all post-HTx)] occurred. Overall survival was excellent, with in-hospital, one-year, and five-year actuarial survival being 92%, 89%, and 80%, respectively.</p><p><strong>Conclusions: </strong>The current series demonstrates that excellent posttransplant outcomes are achievable for patients with Fontan circulation failure using a comprehensive approach including SVAD and HLTx therapies. Pretransplant optimization, sometimes including SVAD implantation, and meticulous operative planning are imperative strategies for successful patient outcomes.</p>","PeriodicalId":94270,"journal":{"name":"World journal for pediatric & congenital heart surgery","volume":" ","pages":"21501351241305127"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal for pediatric & congenital heart surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/21501351241305127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: With an increasing number of Fontan patients surviving into adulthood, the burden of end-stage heart failure is increasing. Prior studies have reported suboptimal heart transplantation (HTx) outcomes. Therefore, the authors describe their institutional experience of HTx in patients with Fontan circulation failure, including en-bloc heart-liver transplantation (HLTx) and pretransplant systemic ventricular assist device (SVAD) therapies.

Methods: All consecutive Fontan-palliated patients undergoing HTx or HLTx between 2013 and 2022 at the authors' institution were included. Pretransplant characteristics and posttransplant outcomes were recorded.

Results: Twenty-six transplant recipients, including 5 (19%) HLTx recipients, were identified. The majority (n = 16, 62%) of patients had a cardiac diagnosis of hypoplastic left heart syndrome. Seven (26%) patients were bridged to transplant on an SVAD; the median duration of support was 104 [IQR 39-543] days. Transplantation occurred at a median of 10.6 [IQR 6.8-15.6] years post-Fontan. Fourteen (54%) patients had ≥1 in-hospital complication and 4 (15%) patients required an in-hospital reoperation. Postdischarge reinterventions included tricuspid valve repair (n = 1, 4%) and retransplantation (n = 1, 4%). Two (8%) in-hospital mortalities [22 days (post-HLTx), 2.9 months (post-HTx] and 4 (15%) postdischarge mortalities [5.4 months, 3.1 years, 5.7 years, 7.1 years (all post-HTx)] occurred. Overall survival was excellent, with in-hospital, one-year, and five-year actuarial survival being 92%, 89%, and 80%, respectively.

Conclusions: The current series demonstrates that excellent posttransplant outcomes are achievable for patients with Fontan circulation failure using a comprehensive approach including SVAD and HLTx therapies. Pretransplant optimization, sometimes including SVAD implantation, and meticulous operative planning are imperative strategies for successful patient outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
采用当代策略的Fontan患者的心脏移植结果:心肝移植和心室辅助装置治疗。
背景:随着越来越多的Fontan患者存活到成年,终末期心力衰竭的负担也在增加。先前的研究报告了次优心脏移植(HTx)的结果。因此,作者描述了他们在Fontan循环衰竭患者中HTx的机构经验,包括整体心肝移植(HLTx)和移植前系统性心室辅助装置(SVAD)治疗。方法:纳入2013年至2022年在作者所在机构接受HTx或HTx治疗的所有连续方丹姑息患者。记录移植前特征和移植后结果。结果:共发现移植受者26例,其中HLTx受者5例(19%)。大多数(n = 16, 62%)患者的心脏诊断为左心发育不全综合征。7例(26%)患者通过SVAD桥接移植;中位支持持续时间为104 [IQR 39-543]天。移植发生的中位时间为fontan术后10.6年[IQR 6.8-15.6]年。14例(54%)患者有≥1种院内并发症,4例(15%)患者需要院内再手术。出院后再干预包括三尖瓣修复(n = 1.4%)和再移植(n = 1.4%)。2例(8%)住院死亡[htx术后22天、2.9个月],4例(15%)出院后死亡[htx术后5.4个月、3.1年、5.7年、7.1年]。总体生存率非常好,住院、1年和5年精算生存率分别为92%、89%和80%。结论:目前的系列研究表明,采用包括SVAD和HLTx治疗在内的综合方法,Fontan循环衰竭患者可以获得良好的移植后预后。移植前优化,有时包括SVAD植入,以及细致的手术计划是患者成功预后的必要策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Contemporary Practice of Native Coarctation in Children Greater Than One Year of Age: A Society of Thoracic Surgeons Analysis. Evaluating Diaphragmatic Paralysis After Pediatric Cardiac Surgery and the Role of Plication in Outcome Improvement: Insights From a Single-Center Experience. Long-Term Coronary Artery Complications Following the Arterial Switch Operation for Transposition of the Great Arteries-A Scoping Review. Neoaortic Dilation and Polyvalvar Dysfunction: The Coexistence of Marfan Syndrome with Hypoplastic Left Heart Syndrome. Pulmonary Atresia and Ventricular Septal Defect: Definitions, Nomenclature, and Classification.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1